PE20070334A1 - COMPOSITIONS AND PHARMACEUTICAL DOSAGE FORMS INCLUDED BY LECOZOTAN - Google Patents
COMPOSITIONS AND PHARMACEUTICAL DOSAGE FORMS INCLUDED BY LECOZOTANInfo
- Publication number
- PE20070334A1 PE20070334A1 PE2006001076A PE2006001076A PE20070334A1 PE 20070334 A1 PE20070334 A1 PE 20070334A1 PE 2006001076 A PE2006001076 A PE 2006001076A PE 2006001076 A PE2006001076 A PE 2006001076A PE 20070334 A1 PE20070334 A1 PE 20070334A1
- Authority
- PE
- Peru
- Prior art keywords
- lecozotan
- propil
- dioxin
- piperazin
- pyridin
- Prior art date
Links
- NRPQELCNMADTOZ-OAQYLSRUSA-N 4-cyano-n-[(2r)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-n-pyridin-2-ylbenzamide Chemical compound C([C@@H](C)N1CCN(CC1)C=1C=2OCCOC=2C=CC=1)N(C=1N=CC=CC=1)C(=O)C1=CC=C(C#N)C=C1 NRPQELCNMADTOZ-OAQYLSRUSA-N 0.000 title abstract 2
- 229950007396 lecozotan Drugs 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000007524 organic acids Chemical class 0.000 abstract 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DERIVADOS DE {(2R)-2-[4-(2,3-DIHIDRO-BENZO[1,4]DIOXIN-5-IL)-PIPERAZIN-1-IL]-PROPIL}-N-PIRIDIN-2-IL Y METABOLITOS, SIENDO PREFERIDO EL COMPUESTO 4-CIANO-N-{(2R)-2-[4-(2,3-DIHIDRO-BENZO[1,4]DIOXIN-5-IL)-PIPERAZIN-1-IL]-PROPIL}-N-PIRIDIN-2-IL-BENZAMIDA O DENOMINADO LECOZOTAN QUE SE ENCUENTRAN BAJO LA FORMA DE PARTICULAS, CON UN DIAMETRO NO MAYOR A 20 MICRONES Y ADEMAS COMPRENDE AL MENOS UN POLIMERO QUE CONTROLA LA VELOCIDAD DE LIBERACION TAL COMO METILCELULOSA; UN ACIDO ORGANICO TAL COMO ACIDO CITRICO O ACIDO ORGANICO POLIFUNCIONAL; UN RELLENADOR TAL COMO CELULOSA MICROCRISTALINA, LACTOSA, CARBONATOS, ENTRE OTROS Y UN LUBRICANTE. TAMBIEN SE REFIERE A UNA FORMA DE DOSIFICACION ORAL QUE LUEGO DE ADMINISTRAR AL PACIENTE ALCANZA UNA CONCENTRACION MAXIMA EN EL PLASMA (Cmax) Y UNA CONCENTRACION EN PLASMA DE 24 HORAS (C24) UNA RELACION MEDIA Cmax/C24 DESDE 5:1 HASTA 1,1:1. ESTOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMERIT REFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING DERIVATIVES OF {(2R) -2- [4- (2,3-DIHYDRO-BENZO [1,4] DIOXIN-5-IL) -PIPERAZIN-1-IL] -PROPIL} - N-PYRIDIN-2-IL AND METABOLITES, THE COMPOUND 4-CYANE-N - {(2R) -2- [4- (2,3-DIHYDRO-BENZO [1,4] DIOXIN-5-IL) being preferred. PIPERAZIN-1-IL] -PROPIL} -N-PYRIDIN-2-IL-BENZAMIDE OR SO-CALLED LECOZOTAN WHICH ARE FOUND IN THE FORM OF PARTICLES, WITH A DIAMETER NOT GREATER THAN 20 MICRONS AND ALSO INCLUDES AT LEAST ONE POLYMER THAT CONTROLS IT OF RELEASE SUCH AS METILCELLULOSE; AN ORGANIC ACID SUCH AS CITRIC ACID OR POLYFUNCTIONAL ORGANIC ACID; A FILLER SUCH AS MICROCRYSTALLINE CELLULOSE, LACTOSE, CARBONATES, AMONG OTHERS AND A LUBRICANT. IT ALSO REFERS TO AN ORAL DOSAGE FORM THAT AFTER ADMINISTERING THE PATIENT REACHES A MAXIMUM CONCENTRATION IN PLASMA (Cmax) AND A CONCENTRATION IN PLASMA OF 24 HOURS (C24) AN AVERAGE RATIO Cmax / C24 FROM 5: 1 TO 1.1 :one. THESE COMPOUNDS ARE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71541705P | 2005-09-09 | 2005-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070334A1 true PE20070334A1 (en) | 2007-05-08 |
Family
ID=37836444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001076A PE20070334A1 (en) | 2005-09-09 | 2006-09-06 | COMPOSITIONS AND PHARMACEUTICAL DOSAGE FORMS INCLUDED BY LECOZOTAN |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1928863A2 (en) |
| JP (1) | JP2009507850A (en) |
| KR (1) | KR20080043855A (en) |
| CN (1) | CN101258146A (en) |
| AR (1) | AR058033A1 (en) |
| AU (1) | AU2006287543A1 (en) |
| BR (1) | BRPI0615771A2 (en) |
| CA (1) | CA2620491A1 (en) |
| CR (1) | CR9800A (en) |
| EC (1) | ECSP088236A (en) |
| GT (1) | GT200600403A (en) |
| IL (1) | IL189827A0 (en) |
| NO (1) | NO20081100L (en) |
| PE (1) | PE20070334A1 (en) |
| RU (1) | RU2008108216A (en) |
| TW (1) | TW200800198A (en) |
| WO (1) | WO2007030589A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
| EP1904066B1 (en) | 2005-07-06 | 2018-05-23 | Sunovion Pharmaceuticals Inc. | COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, for treating MENOPAUSE, perimenopause AND COGNITIVE DISORDERS |
| JP2012526832A (en) * | 2009-05-13 | 2012-11-01 | スノビオン プハルマセウトイカルス インコーポレイテッド | Composition comprising transnorsertraline and serotonin receptor 1A agonist / antagonist and use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1466451B (en) * | 2000-09-29 | 2010-05-12 | 索尔瓦药物有限公司 | Ion-strength independent sustained release pharmacetuical formulation |
| GB2407498B (en) * | 2003-10-30 | 2008-06-11 | Cipla Ltd | Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient |
| US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
| AU2006218845A1 (en) * | 2005-03-01 | 2006-09-08 | Wyeth | Crystalline and amorphous 4-cyano-N{(2R)-2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl)-piperazin-1-yl)-propyl}-N-pyridin-2-yl-benzamide hydrochloride |
-
2006
- 2006-09-06 AU AU2006287543A patent/AU2006287543A1/en not_active Abandoned
- 2006-09-06 GT GT200600403A patent/GT200600403A/en unknown
- 2006-09-06 CN CNA2006800328607A patent/CN101258146A/en active Pending
- 2006-09-06 EP EP06790193A patent/EP1928863A2/en not_active Withdrawn
- 2006-09-06 JP JP2008530186A patent/JP2009507850A/en not_active Withdrawn
- 2006-09-06 WO PCT/US2006/034813 patent/WO2007030589A2/en not_active Ceased
- 2006-09-06 RU RU2008108216/14A patent/RU2008108216A/en not_active Application Discontinuation
- 2006-09-06 CA CA002620491A patent/CA2620491A1/en not_active Abandoned
- 2006-09-06 PE PE2006001076A patent/PE20070334A1/en not_active Application Discontinuation
- 2006-09-06 TW TW095132852A patent/TW200800198A/en unknown
- 2006-09-06 BR BRPI0615771-8A patent/BRPI0615771A2/en not_active Application Discontinuation
- 2006-09-06 KR KR1020087007106A patent/KR20080043855A/en not_active Withdrawn
- 2006-09-06 AR ARP060103880A patent/AR058033A1/en unknown
-
2008
- 2008-02-28 IL IL189827A patent/IL189827A0/en unknown
- 2008-03-03 NO NO20081100A patent/NO20081100L/en not_active Application Discontinuation
- 2008-03-04 EC EC2008008236A patent/ECSP088236A/en unknown
- 2008-03-07 CR CR9800A patent/CR9800A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL189827A0 (en) | 2008-11-03 |
| EP1928863A2 (en) | 2008-06-11 |
| CR9800A (en) | 2008-04-28 |
| AR058033A1 (en) | 2008-01-23 |
| WO2007030589A3 (en) | 2007-11-01 |
| KR20080043855A (en) | 2008-05-19 |
| NO20081100L (en) | 2008-06-03 |
| ECSP088236A (en) | 2008-04-28 |
| JP2009507850A (en) | 2009-02-26 |
| GT200600403A (en) | 2007-09-19 |
| AU2006287543A1 (en) | 2007-03-15 |
| TW200800198A (en) | 2008-01-01 |
| CA2620491A1 (en) | 2007-03-15 |
| RU2008108216A (en) | 2009-10-20 |
| CN101258146A (en) | 2008-09-03 |
| BRPI0615771A2 (en) | 2011-05-24 |
| WO2007030589A2 (en) | 2007-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2471781C2 (en) | Novel disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission | |
| PE20100252A1 (en) | NEW SOLID PHARMACEUTICAL FORMULATIONS INCLUDING 4 - [(3-CHLORO-4-FLUOROPHENYL) AMINO DIMALEATE] -6 - {[4- (N, N-DIMETHYLAMINO) -1-OXO-2-BUTEN-1-IL] AMINO } -7 - ((S) -TETRAHIDROFURAN-3-ILOXI) -QUINAZOLINA | |
| TN2009000180A1 (en) | NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF | |
| PE20081506A1 (en) | ANSAMYCIN FORMULATIONS | |
| CL2009000349A1 (en) | Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease. | |
| CU23551B7 (en) | PROCEDURE FOR THE PRODUCTION OF A SOLID PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION | |
| GEP20084467B (en) | Gamma crystalline form of ivabradine hydrochloride, process for its preparation and pharmaceutical compositions containing it | |
| NO20084853L (en) | Compounds that are agonists of muscarinic receptors and which may be effective in the treatment of pain, Alzheimer's disease and / or schizophrenia | |
| PE20071250A1 (en) | PHARMACEUTICAL FORMULATIONS INCLUDING PLECONARIL | |
| GEP20084466B (en) | Beta d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | |
| MX2011013648A (en) | New compounds, pharmaceutical composition and methods relating thereto. | |
| ATE528306T1 (en) | BENZOXAZEPINE COMPOUNDS, THEIR PREPARATION AND USE | |
| AR047993A1 (en) | PHARMACEUTICAL COMPOSITION THAT PIMOBENDAN INCLUDES | |
| DK1511489T3 (en) | New pharmaceutical compositions containing flibanserin polymorph A | |
| EA200801184A1 (en) | DERIVATIVES OF PIPEREDIN-4-IL-PYRIDAZIN-3-ILAMINE AS FAST DISCRETING ANTAGONISTS OF DOPAMINE 2 RECEPTOR | |
| DE60120109D1 (en) | PROCESS FOR THE PREPARATION OF OPTIC-PURE (R) - AND (S) - DIDESMETHYLSIBUTRAMINE | |
| EA200702253A1 (en) | PHARMACEUTICAL COMPOSITION | |
| ECSP066770A (en) | NEW CUATERNIZED QUINUCLIDINE ESTERS | |
| PE20070334A1 (en) | COMPOSITIONS AND PHARMACEUTICAL DOSAGE FORMS INCLUDED BY LECOZOTAN | |
| JO2937B1 (en) | Peptidic Vasopressin Receptor Agonists | |
| PE20060125A1 (en) | DOSAGE FORMS AND PHARMACEUTICAL COMPOSITIONS INCLUDING 4-CYANE-N - {(2R) -2- [4- (2,3-DIHYDRO-BENZO [1,4] DIOXIN-5-IL) -PIPERAZIN-1-IL] -PROPIL] -N-PYRIDIN-2-IL-BENZAMIDE AND / OR RELATED COMPOUNDS | |
| RU2481344C2 (en) | Substituted (oxazolidinon-5yl-methyl)-2-thiophen-carboxamide and use thereof in blood coagulation | |
| CR10210A (en) | BENZOISOINDOL DERIVATIVES FOR PAIN TREATMENT | |
| ZA200606554B (en) | Pharmaceutical composition for oral application and method for preparing thereof | |
| CL2008003780A1 (en) | Compounds derived from azetidines; preparation procedure; intermediate compounds; pharmaceutical composition; and use for the treatment or prevention of psychiatric disorders, dependence or withdrawal to a substance, cognitive disorders, neurodegenerative diseases, among others. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |